Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Amgen,Carfilzomib,(once-weekly) for the second-line treatment of relapsed or refractory multiple myeloma,Carfilzomib,,
